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Abstract
Background: The role of the Beta2-adrenoceptor (beta2-AR) Gln27Glu polymorphism in the
manifestation of cardiovascular diseases is still unclear.
Methods: In the present study, we evaluated the potential relevance of the c.79 C>G (p.Gln27Glu)
polymorphism of this receptor gene for coronary artery disease (CAD) and its associated risk
factors in Saudi Arabs. Genotyping was performed by PCR using the confronting two-pair primer
(PCR-CTPP) method.
Results: In the general population group (BD) (n = 895), 68.5% were homozygous wild-type C/C,
28.3% were heterozygous C/G and 3.2% were homozygous mutant G/G. Among the CAD patients
(n = 773), 50.6% were homozygous wild-type C/C, 43.6% were heterozygous C/G and 5.8% were
homozygous mutant G/G, while in the angiographed control group (CON) (n = 528), 71.8% were
C/C, 24.4% C/G and 3.8% G/G genotypes. These results indicate that both the C/G (p = < .001)
and G/G (p = .005) genotypes are significantly associated with CAD, when compared to the CON
group. In addition, C/G (p = < .001) and G/G (p = < .001) were significantly associated with CAD,
when compared to the BD group. Furthermore, stepwise logistic regression showed that the
genotype [C/G (p < .001) and G/G (p < .001)] increase the risk of CAD.
Conclusion: These results shows that the Gln27Glu genotypes (homo- or heterozygous) of the
beta2-AR may be independent predictors of severe CAD.
Background
The β2-adrenoceptor (β2-AR) plays an important role in
the parasympathetic and sympathetic regulation of heart
rate and contractility both in intact cardiovascular system
and disease [1]. Apart from its cardiovascular function,
the β2-AR also exerts vasodilatory and relaxing effects on
different types of vascular smooth muscle. Hence, muta-
tions in the gene coding for this protein are likely to have
a great impact on cardiovascular reactivity and function.
The gene is highly polymorphic in humans, the most
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common of which are the three polymorphisms Glu27,
Gly16 and Thr164 that have been invariably associated
with different cardiac risk factors. Besides, there is conflict-
ing data in the literature, specifically with regard to the rel-
evance of the Glu27 polymorphisms for the manifestation
of different cardiovascular diseases and in different popu-
lations. For example, while some investigators found an
association between this polymorphism and obesity in
French population [2], others failed to establish such a
link in various other populations [3-5]. Besides, the Glu27
polymorphism was associated with rheumatoid arthritis
[6], coronary events in elderly patients [7], elevated leptin
and triglycerides levels [8], but not with hypertension [9-
12], blood pressure and heart size [13], obesity [5] and
DM [5]. These partly conflicting reports point to the like-
lihood that the relevance of these gene variants as suscep-
tibility factors for acquiring CAD or its risk factors may
vary among different ethnical groups. In order to test this
notion, in this study we were interested specifically in
evaluating the potential relevance of the Glu27 variant for
CAD manifestation and its risk factors among Arabs, using
the Saudi population as a study model. Our results indi-
cate a strong association between the C/G and G/G geno-
types of the β2-AR gene and CAD in Arabs. Therefore,
these genotypes (C/G or G/G) could be used as a predictor
of severe CAD at least in our population.
Methods
Study population
Three groups of Saudi individuals were recruited for the
present study. The patient group comprised 773 candi-
dates (477 males and 296 females; mean age 53.8 ± 1.08
yr) of Saudi Arabian descent with angiographically docu-
mented CAD (CAD group). The inclusion criteria for
severe CAD involved, among others, the presence of ang-
iographically established narrowing of the coronary ves-
sels by at least 70%. A second group of 528 individuals
(298 males and 230 females, mean age 52.3 ± 1.42 yr)
undergoing surgery for heart valvular diseases and those
who reported with chest pain, but were established to
have clear vessels by angiography, were recruited as con-
trols (CON) group. A further group of 895 healthy Saudi
individuals (519 males and 376 females, mean age 50.5 ±
3.6 yr) visiting the Blood Donor Clinic at King Faisal Spe-
cialist Hospital and Research Centre from January 2003 to
November 2004, were recruited as representing the whole
spectrum of the Saudi general population (BD group).
This study was performed in compliance with the Helsinki
declaration and in accordance with the regulations laid
down by the Hospital Ethics Committee (approval RAC #
2010020) and all participants signed an informed con-
sent.
Five ml of peripheral blood were collected in EDTA tubes
from all participating individuals after obtaining their
written consent. DNA was extracted using the PURGENE
kit from Gentra Systems (Minneapolis, MN, USA), and
stored in aliquots at -20°C until required. Serum choles-
terol and triglyceride levels were measured as routine in
the main Hospital Pathology Laboratory. Triglyceride lev-
els < 1.8 mmol/L and total cholesterol levels < 5.2 mmol/
L were considered normal. Diabetic patients either had a
known history of diabetes mellitus or were diagnosed
according to the American Diabetes Association criteria
[14]. Diagnosis of myocardial infarction was based on the
consensus specified by the European society of cardiology
and the American college of cardiology [15]. Information
about all risk factors was procured either through patient
interviews or by referring to their medical records.
Determination of the β2-AR genotypes
The genotyping for the c.79 C>G (p.Gln27Glu) polymor-
phism of β2-AR was determined by polymerase chain reac-
tion (PCR) procedure using a modified confronting two-
pair primer (PCR-CTPP) method described previously
[16]. As a quality control, we sequenced and confirmed
the genotype status of 288 samples representing the three
different genotypes.
Statistical analysis
Genotype frequencies among the various groups were
compared by Chi-Square test. Multivariable logistic
regression was used to study the effect of the β2-AR geno-
type on CAD status, incorporating other variables, such as
coronary risk factors, into the model. A two-tailed p value
< .05 was considered statistically significant. All analyses
Table 1: Genotypic and allelic distribution of the Gln27Glu polymorphism of β2-AR gene among angiographically confirmed coronary 
artery disease patients (CAD) and blood donors group (BD). CI, confidence interval
CAD (n = 773) BD (n = 895) Odds ratio 95% CI P value
Genotypes
C/C 391 (50.6%) 613 (68.5%) - reference -
C/G 337 (43.6%) 253 (28.3%) 2.09 [1.69 – 2.58] < .001
G/G 45 (5.8%) 29 (3.2%) 2.43 [1.46 – 4.06] < .001
Alleles
C 1119 (72.4%) 1479 (82.6%) - reference -
G 427 (27.6%) 311 (17.4%) 1.81 [1.53 – 2.15] < .001BMC Medical Genetics 2006, 7:31 http://www.biomedcentral.com/1471-2350/7/31
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were performed using the SPSS v.10 (SPSS Inc., Chicago,
IL, USA) statistical analysis software.
Results
In the BD group (n = 895), 613 (68.5%) were
homozygous wild-type C/C, 253 (28.3%) were hetero-
zygous C/G and 29 (3.2%) were homozygous mutant G/
G. Among the severe CAD patients (n = 773), 391
(50.6%) carried the C/C genotype, 337 (43.6%) were het-
erozygous C/G and 45 (5.8%) and were homozygous for
the G/G genotype. Comparison of the CAD with the BD
group, using the C/C wild-type genotype as the reference,
both the C/G and G/G genotypes were associated with
CAD (p = < .001), see Table 1. Furthermore, the frequency
of the Glu27 allele (G allele) was significantly higher in
the CAD group (p = < .001), Table 1.
Among the CON group (n = 528), 379 (71.8%) were C/C,
129 (24.4%) were heterozygous C/G and 20 (3.8%) were
homozygous for the G/G genotype. Comparison of the
CAD and CON groups, using the C/C wild-type genotype
as the reference showed that both the C/G and G/G geno-
types were associated with CAD (p values of < .001 and
.005, respectively), see Table 2. Furthermore, the fre-
quency of the Glu27 allele (G allele) was significantly
higher in the CAD group (p = < .001), Table 2.
Univariate analysis showed that β2-AR genotypes (C/G
and G/G), age and diabetes mellitus were associated with
CAD, whereas elevated cholesterol (p = .313), elevated
triglycerides (p = .220), family history of CAD (p = .395),
gender (p = .057), hypertension (p = .894) and myocardial
infarction (p = .614) were not, see Table 3. Further analy-
sis of the data based the number of vessels affected
showed no association with Glu27 allele distribution
among the CAD group (results not shown). The variables
in Table 3, showing an association (p = < .05) were then
put into a stepwise logistic regression in order to study the
Table 2: Genotypic and allelic distribution of the Gln27Glu polymorphism of β2-AR gene among angiographically confirmed coronary 
artery disease patients (CAD) and angiographed controls (CON). CI, confidence interval
CAD (n = 773) CON (n = 528) Odds ratio 95% CI P value
Genotypes
C/C 391 (50.6%) 379 (71.8%) - reference -
C/G 337 (43.6%) 129 (24.4%) 2.53 [1.97 – 3.24] < .001
G/G 45 (5.8%) 20 (3.8%) 2.18 [1.26 – 3.76] .005
Alleles
C 1119 (72.4%) 887 (84.5%) - reference -
G 427 (27.6%) 163 (15.5%) 2.08 [1.69 – 2.55] < .001
Table 3: Determination of odds ratio for the CAD risk factors among CAD and CON groups
Risk factor Status CAD CON Odds ratio [95% C.I] p value
Genotype C/C 391 379 reference - -
C/G 337 129 2.53 1.96 – 3.27 < .001
G/G 45 20 2.18 1.23 – 3.90 .004
Age < 40 128 113 reference - -
≥ 40 645 415 1.37 1.03 – 1.84 .027
Elevated Chol No 138 106 reference -
Yes 635 422 1.16 0.86 – 1.55 .313
Elevated TG No 208 138 reference - -
Yes 565 390 1.19 0.91 – 1.56 .188
DM No 375 306 reference - -
Yes 398 222 1.46 1.16 – 1.84 < .001
FH No 540 372 reference - -
Yes 233 156 1.03 0.80 – 1.32 .817
Gender F 296 230 reference - -
M 477 298 1.24 0.99 – 1.57 .057
Hypertension No 86 60 reference - -
Yes 687 468 1.02 0.71 – 1.47 .894
MI No 543 364 reference - -
Yes 230 164 0.94 0.73 – 1.20 < .614
Chol, Cholesterol; DM, Diabetes Mellitus; FH, family history; MI, Myocardial infarction on admission; TG, Triglycerides. Elevated serum triglycerides 
(> 1.8 mmol/L); Elevated total cholesterol (> 5.2 mmol/L).BMC Medical Genetics 2006, 7:31 http://www.biomedcentral.com/1471-2350/7/31
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possible combined effect of the genotypes with other risk
factors on CAD manifestation. The only variable retained
in the model was the genotype (p = < .001), see Table 4,
pointing to an association of the genotypes C/G (p = <
.001) and G/G (p = < .001) with severe CAD manifesta-
tion.
It is noteworthy that since the consanguinity rate in the
Saudi population is > 65% [17], it was difficult for us to
test for Hardy-Weinberg equilibrium because random
mating among this population is not satisfied.
Discussion
For determining the genotype frequencies of the β2-AR
gene we selected 895 Saudi blood donors representing the
whole spectrum of the Saudi population. To our knowl-
edge this is the largest group thus far involved in studying
the frequency of the β2-AR (Glu27) genotypes. The
present study shows that the homozygous C/C genotype
of this gene is the most predominant, while the G/G is the
least prevalent in the Saudi population. The frequency of
the C/G genotype (28.3%) was higher than the frequen-
cies of 15, 16, 10, 13, 26 and 19% observed among Gha-
naians, Kenyans, Sudanese, Filipinos, Indians and
Chinese populations respectively [18]. However, the rate
was lower than 32, 50, 53 and 48% observed among Afri-
can Americans, Scottish, Caucasian USA and Swedish
populations respectively [18].
The frequency for the G/G genotype was 3.2%, which is
almost similar to the rate observed among Ghanaians, Fil-
ipinos and Indian populations respectively. However, our
rate was lower than the rates of 21, 15, 14 and 11%
observed among Scottish, Caucasian USA, Swedish and
Sudanese populations respectively [18].
The observed rate of 17% for the Glu27 allele (G allele) is
similar to the 21% found among the African-Americans
[19], but appears to be higher than the 7 and 8% in the
Chinese and Japanese [12] and lower than the frequency
of 34% in Caucasian Americans [19]. Put together, these
observations point to differences in the frequencies of the
C/G and G/G genotypes and the Glu27 allele of the β2-AR
gene among the different populations.
Our results also indicate strong association of both the C/
G and G/G genotypes with the manifestation of severe
CAD in Arabs. However, further studies in larger popula-
tions are required to verify these results. Nonetheless, it is
noteworthy that, while this mutation has been associated
with various CAD risk factors such as obesity [2], rheuma-
toid arthritis [6], coronary events in elderly patients [7],
elevated leptin and triglycerides levels [8] in different pop-
ulations, currently there is hardly any data available in the
literature implicating it in the manifestation of CAD.
Besides, as described previously, the data implicating dif-
ferent β2-AR polymorphisms in these diseases has been
inconsistent, with some studies pointing to an association
and others showing no relationship of these polymor-
phisms with various cardiovascular disorders. Our obser-
vation together with studies by other investigators
furnishes support to the notion that the β2-AR Glu27 pol-
ymorphism may be invariably important for the manifes-
tation of CAD in different populations.
Conclusion
In summary, our results indicate a strong association
between the C/G and G/G genotypes and the Glu27 (G)
allele with severe CAD in Arabs. Therefore, these geno-
types (C/G or G/G) could be used as a predictor of severe
CAD at least in this population.
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